Glaukos Corp GKOS
NYSE · United States · Health Technology
$164.19+5.64 (+3.56%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
ALISO VIEJO, Calif., September 23, 2026--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the launch of Could it be KC?, a new disease awareness and educational campaign launching today with expanding activities planned in 2027 aimed at improving recognition and earlier detection of keratoconus (KC), a rare, progressive, sight-threatening
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Glaukos has delivered very strong long term share gains, which puts a spotlight on whether the current US$159.86 price still lines up with what the company is generating in sales. After a run like this, the question is how much of that performance is already reflected in the revenue multiple investors are paying today. Over the past 5 years the stock has gained 219.9%, which puts a lot of weight on whether the sales base can support that kind of re-rating. The business model is heavily tied...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.